Gemphire Therapeutics (NASDAQ:GEMP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, November 17th.
According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
A number of other research firms also recently issued reports on GEMP. Jefferies Group lifted their price objective on Gemphire Therapeutics to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, August 1st. Canaccord Genuity set a $31.00 price objective on Gemphire Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Roth Capital began coverage on Gemphire Therapeutics in a report on Thursday, October 19th. They issued a “buy” rating and a $30.00 target price for the company. Piper Jaffray Companies reiterated an “overweight” rating and issued a $22.00 target price on shares of Gemphire Therapeutics in a report on Friday, October 27th. Finally, HC Wainwright began coverage on Gemphire Therapeutics in a report on Thursday, August 31st. They issued a “buy” rating and a $21.00 target price for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Gemphire Therapeutics has a consensus rating of “Buy” and a consensus price target of $22.17.
Gemphire Therapeutics (NASDAQ:GEMP) traded down $0.24 during trading hours on Friday, reaching $8.02. The company’s stock had a trading volume of 20,547 shares, compared to its average volume of 65,246. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.17 and a current ratio of 4.17. Gemphire Therapeutics has a 1-year low of $7.20 and a 1-year high of $21.59.
Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.14). equities analysts expect that Gemphire Therapeutics will post -3.26 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC purchased a new position in shares of Gemphire Therapeutics in the 2nd quarter worth approximately $139,000. Renaissance Technologies LLC purchased a new position in shares of Gemphire Therapeutics in the 1st quarter worth approximately $184,000. Vanguard Group Inc. boosted its holdings in shares of Gemphire Therapeutics by 137.6% in the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after purchasing an additional 17,892 shares during the period. GM Advisory Group Inc. purchased a new position in Gemphire Therapeutics during the 2nd quarter valued at $457,000. Finally, Comerica Bank purchased a new position in Gemphire Therapeutics during the 3rd quarter valued at $850,000. Hedge funds and other institutional investors own 32.11% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Gemphire Therapeutics (GEMP) Downgraded to “Hold” at Zacks Investment Research” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/05/zacks-investment-research-lowers-gemphire-therapeutics-inc-gemp-to-hold.html.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.